Overview
November 13-14: Meeting
The DIA Canada Annual Meeting will deliver a comprehensive overview of the current pharmaceutical, medical device, and/or diagnostic landscapes in Canada, while sharing insights into Canada’s broader role in global healthcare product development and is separated into three tracks: Regulatory, Clinical and Pharmacovigilance. This meeting will connect attendees with leaders and experts in academia and those involved in the regulatory, clinical, and pharmacovigilance functional areas in the pharmaceutical and medical device industry to explore best practices, lessons learned, and problem-solving strategies effecting stakeholders in Canada.
While we develop our 2023 agenda, please take a moment to review the 2022 final agenda.
NEW FOR 2023 – Call for Abstracts now open!
Are you a professional involved in the regulatory, clinical or pharmacovigilance functional areas within a company or organization working on pharmaceuticals, medical devices, and/or diagnostics in Canada? If so, DIA wants to hear from you! The Canada Annual Meeting Program Committee is seeking proposals for Presentations, Sessions, and Short Courses on the following topics of interest as it relates to our three tracks, Regulatory, Clinical, and Pharmacovigilance. Deadline to submit is Monday, April 17.
View Guidelines | Submit Here.
Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.
Participant Testimonials
Very insightful conference. Time well invested.” - Thierry Page, Executive VP, COO, Starpax Biopharma Inc.
“The best conference for Canadian content of 2022.” - Patricia Smith, Director, Regulatory Affairs, QA and PV, Otsuka Canada Pharmaceutical Inc.
Featured
Who should attend?
-
Meeting Designed For
Join professionals interested in a comprehensive overview of the current pharmaceuticals and device landscape in Canada:
- Pharmacovigilance
- Clinical Research, Management, Safety & Ops
- Medical Affairs and Communication
- Quality Assurance Control
- Public/Corporate Policy & Regulatory Affairs
- R&D and Risk Management
- Project Management & eSubmissions
- Real-World Evidence and Statistics
Program Committee
-
Maria Anillo, MSc • Senior Associate, Established Products and Regulatory Operations
Boehringer Ingelheim (Canada) Ltd., Canada -
Marcia Bailey, BSN, MHS, RN • Safety Evaluation & Risk Management Scientific Director
GSK, Canada -
Vatche Bartekian, MSc • President
Vantage BioTrials, Canada -
Mandy Collier • Director, Health Products and Food Branch
Health Canada, Canada -
Melanie Cote, MS • Senior Manager, Regulatory Affairs
Otsuka Canada Pharmaceutical Inc., Canada -
My Dang • Senior Manager, Regulatory Affairs and Quality Assurance
Knight Therapeutics Inc. , Canada -
Tharany Ganesh, MSc • Director, Regulatory Affairs & Quality Assurance
AstraZeneca Canada Inc., Canada -
Lorella Garofalo, PhD • Head of Regulatory Sciences
Pfizer Canada, Canada -
Marie-France Goyer • Director, Clinical Operations
Abcellera, Canada -
Brenda Gryfe, MSc • Director, Regulatory Affairs
TPIreg/ Innomar Strategies, Canada -
Oxana Iliach, PhD • Sr. Director, Regulatory Strategy
Certara, Canada -
Agnes Jankowicz, MS • Vice President, Pharmacovigilance
Veristat, Canada -
Nadiya Jirova • Manager, Bureau of Biologics, Radiopharmaceuticals and Self-Care Products, MHPD
Health Canada, Canada -
Yatika Kohli, PhD, MBA • Executive Director - Global Regulatory Affairs
NoNO Inc, Canada -
Myriam Salem, MSc • Senior Corporate Regulatory and Enforcement Advisor
Health Canada, Canada -
Marcia Sam • Regulatory Affairs Strategy and Policy Manager
Hoffmann-La Roche Canada Limited, Canada -
Vanessa Zapata • Associate Director, Regional Pharmacovigilance Officer
Merck Canada Inc., Canada -
Zohra Douida, MPharm, MS, MSc • Head, Regulatory Affairs Canada
Indivior Canada Ltd., Canada -
Amber McLeod, PhD • Lead, Regulatory Affairs
Abbvie Corporation, Canada
Contact us
Registration Questions?
Additional Information
Discover DIA’s Live In-Person EventsDownload and fill out our Justification Letter
